MedAvail Holdings, Inc.: Nasdaq/NYSE listing notice — MedAvail receives Nasdaq delinquency notice for late Q3 10-Q filing

MedAvail Holdings, Inc.

Nasdaq letter dated Nov 16, 2023 cites failure to timely file Q3 10-Q (Rule 5250(c)(1)).
Company has 60 days to submit a compliance plan; Nasdaq may grant up to 180 days (until May 13, 2024).
No immediate effect on listing or trading of MedAvail common stock on Nasdaq Capital Market.
If plan rejected, MedAvail may appeal to a Nasdaq hearings panel.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MedAvail Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

November 16, 2023, MedAvail Holdings, Inc. (the “Company”) received a delinquency notification letter (the “Delinquency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the three months ended September 30, 2023, the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). The Delinquency Letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasda

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001402479-23-000100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.